New hope for rare liver disease: libevitug enters final trial phase
NCT ID NCT07499544
First seen Apr 04, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study tests a new drug called libevitug for people with chronic hepatitis D, a serious liver infection. About 160 adults will receive either a low or high dose of the drug every two weeks for 96 weeks, or be placed in a control group that starts treatment later. The goal is to see if libevitug can lower the virus level and improve liver health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS D INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.